Does prostaglandin D2 hold the cure to male pattern baldness?

    March 2014 in “Experimental Dermatology
    Ashley Nieves, Luis A. Garza
    Image of study
    TLDR Prostaglandin D₂ might be targeted for new male pattern baldness treatments.
    The document from 2014 explores the connection between Prostaglandin D₂ (PGD₂) and androgenetic alopecia (AGA), or male pattern baldness, noting that PGD₂ levels are higher in the balding areas of men with AGA and can inhibit hair growth. It identifies the enzyme prostaglandin D₂ synthase (PTGDS) and its receptor GPR44 as key components in this process and suggests that targeting these could lead to new treatments for AGA. The paper calls for further research to confirm the role of PGD₂ in hair loss, including studies on its effects throughout the hair cycle, its involvement in other types of hair loss, and the potential for reversing hair miniaturization by inhibiting PGD₂ or GPR44. The research was supported by NIAMS/NIH grant R01AR064297 and involved input from experts in the field, with no conflicts of interest declared by the authors.
    View this study on europepmc.org →

    Cited in this study

    Related